Thank you for subscribing!
Learn More about Next Investors - Experts in Biotech Stocks
Next Investors Feb 28, 2022
Our 2021 Biotech Pick of the Year Dimerix (ASX:DXB) released its half year report last Thursday, updating investors on ethics approvals for its Phase III clinical trial for FSGS (a rare kidney disease) and closing in on important milestones for TWO of its Phase III COVID-19 studies.
Next Investors Feb 18, 2022
Today we are finally announcing a new investment in the Next Investors portfolio. Arovella Therapeutics (ASX:ALA) is a small ASX biotech going after a unique solution to the scourge of cancer - with cutting edge technology licensed from some of the foremost cancer research institutions - and has attracted big names to the project.
Next Investors Feb 01, 2022
Dimerix (ASX:DXB) just delivered significant progress on its Phase III Clinical Trial for FSGS, with the first EU regulatory approval given for DXB’s kidney disease study in Denmark... earlier than expected.
Next Investors Oct 25, 2021
Today Creso Pharma’s (ASX:CPH) announced the acquisition of a range of CBD brand and product assets that deliver anti-inflammatory relief to professional and amateur athletes suffering from chronic muscle and joint pain.
Get expert stock analysis direct in your inbox
Next Investors Sep 27, 2021
On Friday last week, DXB announced that the main drug regulator in India has recommended approval for DXB’s Phase III clinical trials on COVID-19 treatment, specifically for patients with respiratory complications intended for hospitalisation — its CLARITY 2.0 study.
Next Investors Aug 17, 2021
CPH yesterday went on to announce the successful grant of a rare “Controlled Drugs and Substances license” licence for Haluenex in Canada, another positive step in their psychedelics story.
Next Investors Aug 16, 2021
Today we announce the fourth addition to our portfolio for 2021. Today we are adding Dimerix (ASX:DXB) to the Next Investors portfolio as our inaugural Biotech Pick of the Year for 2021.
Next Investors Archived Aug 01, 2021
eSense-Lab Ltd (ASX: ESE) has signed a research agreement with the Israeli Ministry of Health to commence a research project at the Central Virology lab in the Chaim Sheba Medical Centre — the largest hospital in Israel — to test its proprietary TRP-ENV™ compounds for a coronaviruses.
Next Investors Jul 01, 2021
Creso Pharma Ltd (ASX:CPH | OTC:COPHF) has just confirmed two consecutive quarters of record revenue growth. CPH posted $1.71M revenue this quarter - up from $1.38M in the previous quarter - that’s 24% growth.
Next Investors Jun 17, 2021
Today Creso Pharma (ASX: CPH | OTC: COPHF) announced its plans to merge with a Canadian listed psychedelics company called Red Light Holland.
Next Investors Jun 11, 2021
Creso Pharma (ASX:CPH) today announced its listing in the US, and the market is opening in around 12 hours - the US pool of investors is huge and they have a big appetite for psychedelics and cannabis stocks.
Next Investors May 14, 2021
Creso Pharma (ASX: CPH)’s acquisition target Halucenex just picked up an extra 10g of ‘hard-to-access’ synthetic psilocybin - and now has 22.3g in total.
Next Investors Apr 27, 2021
Creso Pharma (ASX: CPH) is listing on the US markets within weeks (via an OTC listing), but a similar company called MindMed is listing on the NASDAQ in 8 hours from now.
Next Investors Mar 26, 2021
Creso Pharma (ASX: CPH) is edging closer to becoming part of our long term portfolio. CPH just raised $18M, which significantly shores up the balance sheet - another tick in the box for us as CPH builds trust to enter our long term portfolio.
Next Investors Mar 15, 2021
Once again, medicinal cannabis company Creso Pharma (ASX: CPH) keeps pleasantly surprising us. Today they have REALLY surprised us by announcing they have acquired a Psychedelics company.
Creso Pharma (ASX: CPH) will be the first ASX listed stock to acquire 100% of a psychedelics company. CPH is set to acquire Canada based Halucenex Life Sciences Inc., an established psychedelics company developing treatments for a range of mental illnesses.
Next Investors Mar 01, 2021
Creso Pharma (ASX: CPH) just released its preliminary financial reports for the year, which as expected show a bunch of impairments, debt clean ups and other scary looking one off costs that come with a balance sheet clean up - these are all out of the way now.
Creso Pharma (ASX: CPH | FRA: 1X8) is set to distribute its range of CBD and hemp animal health anibidiol® products throughout the US, following a deal signed with CERES Natural Remedies.
Join Our Mailing List
